Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced that it is actively recruiting for more skilled personnel at Queenborough ahead of the launch of its new development centre at the site. This initiative follows the company’s strategic decision to relocate development and clinical manufacturing services from Nottingham to Queenborough.

Consequently, the company is looking for talented individuals to come and join the organisation in a variety of roles. An active plan is in place to recruit additional staff, over the course of the next 12 to 24 months, across formulation and analytical science, Quality Control, business development and project management disciplines.

Ian Muir, Managing Director at Aesica Pharmaceuticals commented: “We feel that the range and depth of experience and services that our Queenborough development centre will offer on site, provides present and future staff real scope for extensive and broad ranging career experience.”

Please click here if you are interested in applying for a career at the Aesica Queenborough site.

About Aesica
• Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

About Consort Medical:
• Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities

About Bespak:
• Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740/6745 or e-mail;


  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts